Histogen Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Susan Knudson

İcra Kurulu Başkanı

US$681.2k

Toplam tazminat

CEO maaş yüzdesi	68.4%
CEO görev süresi	3.7yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	9.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Susan Knudson'un ücretlendirmesi Histogen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$681k	US$466k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$539k	US$385k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$767k	US$212k	-US$19m

Tazminat ve Piyasa: Susan 'nin toplam tazminatı ($USD 681.24K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 488.36K ).

Tazminat ve Kazançlar: Susan şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Susan Knudson (59 yo)

3.7yrs

Görev süresi

US$681,237

Tazminat

Ms. Susan A. Knudson is Chief Financial Officer of Histogen Inc. since May 2020 and serves as its Chief Compliance Officer and Corporate Secretary and serves as its Chief Operations Officer since March 10,...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Kisner	Independent Non-Executive Chairman	9.9yrs	US$52.70k	0.0011% € 14.6
Neil Sadick	Member of the Scientific Advisory Board	13.5yrs	Veri yok	Veri yok
Craig Ziering	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Susan Windham-Bannister	Independent Director	2.8yrs	US$57.70k	0% € 0
Rochelle Fuhrmann	Independent Director	2.8yrs	US$58.81k	0% € 0
Dale DeVore	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
David Crean	Independent Director	5.8yrs	US$85.24k	0% € 0
Jonathan Jackson	Independent Director	13.1yrs	US$51.05k	2.76% € 36.7k
David Easter	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brian Satz	Independent Director	11.2yrs	US$56.70k	0.0017% € 22.5

9.9yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.9 yıldır).

Histogen Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Histogen Inc. Announces Executive Changes

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen Inc., Annual General Meeting, Jun 01, 2022

Histogen Inc. Announces Board Changes

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Recent updates

Histogen Inc. Filed for Bankruptcy

Histogen Inc. Files Form 15

Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index

Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration

Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index

Histogen Inc. Announces Executive Changes

Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market

Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen Inc. to Report Q2, 2022 Results on Aug 11, 2022

Histogen Inc. announced that it expects to receive $5 million in funding

Histogen Announces 1-for-20 Reverse Stock Split

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)

Histogen Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Histogen Inc. to Report Q4, 2021 Results on Mar 10, 2022

Histogen Not Regained Compliance with the Minimum Bid Price Requirement

Histogen Inc. announced that it has received $3.500001 million in funding

Histogen Inc. announced that it expects to receive $3.500001 million in funding

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.27 loss in 3Q 2020)

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

Histogen Inc. and its partner Amerimmune LLC Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $6.57503 million.

Histogen Provides Update on its Development Programs and Pipeline Focus

Histogen and Amerimmune Reports Publication on Emricasan in COVID-19

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)

Histogen Provides Business Update

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic Covid-19 Patients

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)

Histogen Inc. Announces Board Changes

Independent Director has left the company

Histogen Inc. to Report Q4, 2020 Results on Mar 11, 2021

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day high: €1.51

Histogen Inc. Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $14 million.

New 90-day low: €0.63

New 90-day low: €0.96

Histogen Inc. Announces Filing an Investigational New Drug Application for HST-003

New 90-day low: €1.06

Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $4.500016 million.

Histogen Inc. to Report Q3, 2020 Results on Nov 12, 2020

Histogen Inc. and Amerimmune Llc Enters into A Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of Covid-19

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Histogen Announces Update for its HST-002 Dermal Filler Program

New 90-day low: €1.31

Histogen Inc. Announces Phase 1/2 Clinical Trial Designed to Evaluate HST-003

Earnings released

Histogen Inc. to Report Q2, 2020 Results on Aug 13, 2020